Ballantyne, Christie M <br/><br/>
Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia.  [electronic resource] 

 -  The American journal of cardiology  May 2015 
 - 1212-21 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1879-1913 
<br/><br/><label>Standard No.: </label>10.1016/j.amjcard.2015.02.006  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Antibodies, Monoclonal, Humanized--administration & dosage<br/>Cholesterol, LDL--blood<br/>Cohort Studies<br/>Dose-Response Relationship, Drug<br/>Double-Blind Method<br/>Drug Administration Schedule<br/>Drug Therapy, Combination<br/>Female<br/>Humans<br/>Hydroxymethylglutaryl-CoA Reductase Inhibitors--therapeutic use<br/>Hypercholesterolemia--blood<br/>Injections, Subcutaneous<br/>Male<br/>Middle Aged<br/>Proprotein Convertase 9<br/>Proprotein Convertases--administration & dosage<br/>Serine Endopeptidases--administration & dosage<br/>Treatment Outcome